Biopharmaceutical giant to focus on CDO businessSamsung BioLogics, a biopharmaceutical affiliate of South Korean conglomerate Samsung Group, launched its first overseas research and development center in San Francisco on Oct. 29.The Incheon-based outfit, west of Seoul, said that the research unit is
Korean bio company signs $331 million dealSamsung BioLogics said on September 22 that the South Korean firm had signed a contract manufacturing organization (CMO) deal with Astra Zeneca, which is valued at least $330.8 million.Samsung said that the contract is a follow-up to the two outfits’ letter
Two Korean companies enter into agreement for new drugSamsung BioLogics, South Korea’s first-tier biosimilar company, teams up with STCube to develop and manufacture an anti-cancer drug candidate, dubbed STT-003 antibody.The Incheon-based outfit announced on March 3 that under the two-way agreement,
Operating profit skyrockets almost 65%Samsung BioLogics, South Korea’s top-tier biosimilar company, saw its bottom line jump almost 65 percent last year thanks to its improved operation.The Incheon-based outfit announced Jan. 22 that its 2019 operating profit amounted to 91.7 billion won ($79 millio